Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Phase 2 data showing 24% body weight loss is in humans, not mice but Phase 3 scale and long-term safety data are still pending
GHK-Cu adds another layer of concern because FDA has specifically discussed immunogenicity risk for injectable GHK-Cu related to potential aggregation and peptide-related impurities
Ask the platform directly: which pharmacy compounds your medication, and is it a 503B outsourcing facility registered with the FDA
For a full list of current holdings, please visit www.temaetfs.com/hrts Why invest in Tema GLP-1 & weight loss ETF The weight loss drug market could potentially crest $500bn in size
US$ 29.95
US$ 26.49
US$ 24.51
US$ 21.75
US$ 20.23
US$ 24.99
US$ 24.26
US$ 20.82
